Skip to content
To the full analysis

Pacira BioSciences stock: balance sheet and debt

PCRX
$36.46Closing price of 12 Nov 2026MEQIRI Score 58 out of 100

Pacira BioSciences has a debt to equity ratio of 0.66 and an interest coverage of 2.2x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.66
Interest coverage
2.2x
Current ratio
4.54
Cash & equivalents
$238.42M
Total assets
$1.26B
Equity ratio
54.8%
Goodwill
$20.21M
Plus intangible assets of $368.1M
Net debt
$215.96M

Total assets and equity ratio

How large the balance sheet of Pacira BioSciences, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2008$50.54M$13.08Mnot split out14.8%−$12.39M
2009$43.95M$11.18Mnot split out−52.2%−$7.08M
2010$66.56M$8.91Mnot split out−72.7%−$1.08M
2011$113.49M$5.26Mnot split out42.5%−$47.82M
2012$112.05M$11.51M$8.3M58.8%−$16.53M
2013$169.82M$11.49M$10.33M24.3%$26.81M
2014$326.07M$24.16M$23.76M52.5%−$55.07M
2015$389.62M$30.96M$30.88M56.1%−$53.04M
2016$391.47M$46.74M$46.74M55.9%−$63.86M
2017$628.37M$55.2M$55.2M44.5%−$34.85M
2018$689.35M$62.04M$62.04M46.6%−$92.52M
2019$831.07M$203.93M$99.55M42.7%$59.97M
2020$1.27B$196.07M$99.55M48.6%$19.47M
2021$2.08B$769.14M$145.18M35.2%$472.44M
2022$1.68B$703.79M$163.24M46.1%$474.74M
2023$1.57B$646.5M$163.24M55.3%$307.46M
2024$1.55B$425.97Mnot split out50.1%$154.24M
2025$1.26B$388.31M$20.21M54.8%$215.96M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2008$12.39M$7.49M$00
2009$7.08M−$22.95M$00
2010$26.13M−$48.38M$25.05M−0.52
2011$76.15M$48.27M$28.33M0.59
2012$42.57M$65.86M$26.05M0.4
2013$72.15M$41.25M$98.96M2.4
2014$158.17M$171.15M$103.1M0.6
2015$158.97M$218.39M$105.93M0.49
2016$172.6M$218.98M$108.74M0.5
2017$311.35M$279.48M$276.5M0.99
2018$383.45M$321.23M$290.93M0.91
2019$291.95M$354.94M$351.92M0.99
2020$521.66M$619.69M$541.13M0.87
2021$656.41M$730.41M$1.13B1.55
2022$288.65M$775.01M$763.39M0.99
2023$278.58M$870.13M$586.04M0.67
2024$484.62M$778.35M$638.85M0.82
2025$238.42M$693.11M$454.38M0.66

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy